Arcellx Inc ACLX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
54.50UNCH (UNCH)
Volume
104,259
Close
54.50quote price arrow up+0.95 (+1.77%)
Volume
587,923
52 week range
30.74 - 75.10
Loading...
  • Open53.24
  • Day High54.89
  • Day Low52.59
  • Prev Close53.55
  • 52 Week High75.10
  • 52 Week High Date03/07/24
  • 52 Week Low30.74
  • 52 Week Low Date07/05/23

Key Stats

  • Market Cap2.904B
  • Shares Out53.29M
  • 10 Day Average Volume0.46M
  • Dividend-
  • Dividend Yield-
  • Beta0.02
  • YTD % Change-1.8

KEY STATS

  • Open53.24
  • Day High54.89
  • Day Low52.59
  • Prev Close53.55
  • 52 Week High75.10
  • 52 Week High Date03/07/24
  • 52 Week Low30.74
  • 52 Week Low Date07/05/23
  • Market Cap2.904B
  • Shares Out53.29M
  • 10 Day Average Volume0.46M
  • Dividend-
  • Dividend Yield-
  • Beta0.02
  • YTD % Change-1.8

RATIOS/PROFITABILITY

  • EPS (TTM)-1.49
  • P/E (TTM)-36.65
  • Fwd P/E (NTM)-28.34
  • EBITDA (TTM)-87.84M
  • ROE (TTM)-20.48%
  • Revenue (TTM)110.319M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-64.08%
  • Debt To Equity (MRQ)8.09%

EVENTS

  • Earnings Date05/10/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Arcellx Inc

 

Profile

MORE
Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company’s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage...
Rami Elghandour
Chairman of the Board, President, Chief Executive Officer
Michelle Gilson
Chief Financial Officer
Address
800 Bridge Parkway
Redwood City, CA
94065
United States

Top Peers

SYMBOLLASTCHG%CHG
ARWR
Arrowhead Pharmaceuticals Inc
22.61+0.08+0.36%
IDYA
IDEAYA Biosciences Inc
37.62-2.55-6.35%
XENE
Xenon Pharmaceuticals Inc
40.31-1.32-3.17%
SWTX
SpringWorks Therapeutics Inc
42.47-1.64-3.72%
ARVN
Arvinas Inc
34.29+0.84+2.51%